# Shunji Takahashi

Source: https://onco.cc/people/takahashi-shunji/  
OnCo record `takahashi-shunji` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Shunji Takahashi leads medical oncology and early-phase trials at Japan's oldest cancer institute.

## Summary

Shunji Takahashi is Director of the Department of Medical Oncology at the Cancer Institute Hospital of JFCR, Japan's oldest cancer institute. He leads medical oncology and early-phase trials there, running phase 1 and rare-cancer studies, including sarcoma, and the hospital's genomic medicine programme built on comprehensive genomic profiling. His publications include a phase 1 study of the MDM2 inhibitor milademetan in Japanese patients with solid tumours, a phase 1 study of dasatinib in Japanese patients with solid tumours, and an integrated analysis of osteonecrosis of the jaw across three phase 3 trials in patients with bone metastases. His interests are phase 1 trials, rare cancers and genomic medicine.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Department of Medical Oncology, Cancer Institute Hospital of JFCR
- Specialisms: Medical oncology; Phase 1 trials; Rare cancers; Genomic medicine

## Sources

- Cancer Institute Hospital of JFCR: https://www.jfcr.or.jp/english/
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Takahashi%20S%5BAuthor%5D%20Cancer%20Institute%20Hospital%20JFCR

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/)
- institutions: [Cancer Institute Hospital of JFCR](https://onco.cc/institutions/jfcr/)
- journals: [Cancer science](https://onco.cc/journals/cancer-science/)

---
JSON: https://onco.cc/api/v1/entities/takahashi-shunji.json